An Exploratory Phase 1/2 Trial to Determine Recommended Phase 2 Dose (RP2D), Safety and Preliminary Efficacy of bb2121 (Ide-cel) Combinations in Subjects with Refractory/Relapsed Multiple Myeloma (KarMMa-7)

Administered By

Awarded By

Contributors

Start/End

  • January 3, 2022 - December 31, 2026